Elopak's European Aseptic And Fresh Carton Sales Rose 10.7% While America Stood Still On Rationed Board

My view is simple. Elopak's American carton sales did not stand still because dairies stopped buying cartons. They held flat at EUR 85.5m for the quarter while Europe's rose 10.7%. The board ran short, so supply wrote the number before demand could.

What the quarter actually showed

Elopak reported its third quarter on 27 October. Revenue reached EUR 308.4m, up 6.5% on the year. Trading profit came in at EUR 51.9m, a record for a quarter at the group. The margin on it was 16.8%, against 17.0% a year earlier. So sales grew and the margin slipped at the same time. That happens because the extra sales arrived with extra cost. Board bought away from the usual mill costs more to buy. It travels further to reach the plant. More of it ends up as waste when the line runs it. Insurance money has started to come back against those costs. More of it is due, and it lands later than the cost did. The group also carries a new 50% American duty on caps shipped in from Canada. Cartons and board moving the other way are still clear of it.

Europe carried it, and surcharges did much of the work

The European side did the lifting. Its sales rose 7.5% to EUR 218.1m, with cartons and closures up 10.7%. Elopak said buyer surcharges fully covered higher input costs this time. In the spring they covered only part of them. Here is why that gap matters so much. A surcharge clause resets on a published price after the cost has landed. The maker carries the rise for a quarter and bills it the quarter after. So a line that reads as growth can be an old cost coming home. Carton volume did grow as well, in UHT long-life milk and in fresh dairy. Germany led that, and Roll Fed packs grew on new work in Poland. Volumes went the other way in the Middle East and North Africa, on price and one lost tender. India was a shade lower. Machine sales tell a third story. Group equipment sales fell to EUR 27.7m for the nine months, from EUR 49.7m. The reason is simple. More fillers are going out on lease rather than being sold outright. A leased filler brings in almost nothing in the year it starts work.

The American carton line did not move

The American business looks healthy at first glance. Sales there rose 5.9% to EUR 97.5m. The cartons and closures inside that were flat at EUR 85.5m. The growth came from machines and spares instead. Equipment sales in the region reached EUR 6.1m, close to double the year before. School milk drove most of those commissions. That happens because Elopak held the board it could get for the buyers it already had. A carton maker cannot sign a new dairy it may not be able to supply. Losing a contract on short shipments costs more than never taking it. So the quarter shows new lines being started while the carton volume behind them waits. A region can look busy on equipment and go nowhere on packs.

What a supply ceiling costs, and who pays it

The cost shows up in the margin. The American margin fell to 20.6% from 23.8%. Elopak said it would have been about 23% without the supply trouble. The mill behind the shortage is still not running properly. Most of its people went back to work in October, five months after the accident that stopped it. The owner has agreed to keep paying idled staff into January. That matters because insurance covers the maker's extra cost rather than the buyer's missing cartons. A dairy with orders to fill goes and finds a second supplier. Qualifying that supplier takes months of trials and paperwork. Here is the part that lasts. A buyer who has done that work rarely hands the volume back in full. So the bill for a mill failure is split. The converter claims its costs. The market share moves anyway.

Why a carton maker's sales line is a poor read on aseptic packs

This is where market sizing goes wrong. Elopak made 16 billion cartons in 2025, and aseptic work was 31% of its carton sales. The rest is chilled fresh milk and juice. Zenith counts about 344 billion aseptic packs filled around the world in that same year. So Elopak is a large fresh carton maker and a modest aseptic one. Cartons still carry 66.5% of world aseptic volume, so carton makers are the right place to look. The mechanism is simple. A revenue line mixes price, surcharge, machines and packs together. Packs are the only part of it that measures the market. A group can grow 6.5% on surcharge recovery while the packs stand still. The reverse happens too. A maker can place more fillers on lease and show less equipment revenue for it. Anyone sizing a market from supplier sales alone will read both of those backwards.

The Zenith read on where this lands

We think American carton volume at Elopak stays capped into the first half of next year. The company guides to a full-year margin of about 15%. That sits below what it has just printed. So the group is telling the market its own supply has not been fixed. The mill is the gate, and it has no public date for full output. That matters because a converter cannot promise volume off a mill with no restart date. We therefore expect two more quarters where machines and spares grow faster than cartons. The figure we watch is the American cartons and closures line. When it moves off EUR 85.5m, the board has come back and the ceiling has gone. A third line goes into Arkansas in the second half of 2027. It is aimed at small school packs rather than long-life work. That tells you where Elopak thinks its American growth sits. Our opening claim settles here. Supply, rather than demand, wrote this quarter's American number, and a market read off that number will be wrong.

We will be watching what this does to North American carton volumes as board supply comes back. That region is one of the markets we track in our Global Aseptic Packaging Market Report 2026. It counts packs and litres by market, pack type and pack size. A supply-capped year then shows up as what it is.